FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2910394076> ?p ?o ?g. }

• W2910394076 abstract "Background Behcet’s Disease uveitis(BDU) mostly involved bilateral panuveitis and retinal vasculitis, which are very challenging to treat. Interferon alfa-2a (IFNα 2a) has been shown to have comparable effectiveness and tolerance profiles for BDU as tumour necrosis factor (TNF) inhibitors in a number of studies with a much lower cost. IFNα−2a treatment combined with corticosteroids without immunosuppressants was common in previous studies. We herein report a cohort of highly refractory BDU patients who experienced recurrence despite aggressive treatment with multiple immunosuppressants at their therapeutic doses. Objectives To investigate the efficacy and safety of IFNα2a treatment in combination with corticosteroids and immunosuppressants in patients with refractory BDU. Methods Clinical records of refractory BDU patients who underwent IFNα2a treatment in our centre between 2015 and 2017 were retrospectively reviewed. IFNα2a was initially given 3.0 million IU (MIU) subcutaneously daily for 4 weeks, on the basis of conventional corticosteroid and immunosuppressive therapy. The dosage was gradually tapered down to 3.0 MIU three times or even once per week for maintenance. Primary outcome measure was success rate and changes in ocular relapse rates before and after initiation of IFN-α2a treatment. Disease activity, corticosteroid- and immunosuppressive agent-sparing effects and potential side effects were considered to be secondary outcomes. Results A total of 26 patients (23 males and 3 females) were included, with a median disease course of 41 months (range 5–168) before IFNα 2a treatment. No major organ involvement except for ocular inflammation was noted. Concomitant medical conditions include chronic hepatitis B virus infection in 2 patients, pulmonary tuberculosis in 1 patient who was treated with antitubercular agents in the meanwhile. Prior to IFNα2a therapy, the median minimum dosage of corticosteroids was 20 (range 15–45) mg/day prednisone or equivalent, and 17 patients (65.4%) were treated with at least two immunosuppressive agents. Four received short terms of TNFα inhibitor therapy but stopped due to economic burden. Severe side effects related to previous therapies including femoral head necrosis and secondary hypertension were observed in some patients. Treatment success of IFNα2a was achieved in the majority of the patients (24/26, 92.3%). During a mean follow-up of IFNα2a therapy for 13.6±6.0 months, the median rate of uveitis relapse decreased notably from 8 per patient-year (range 2–12) to 0 per patient-year (range 0–6) (p=0.000008). Oral corticosteroids were successfully decreased in 20 cases (76.9%) and completely discontinued in 2 patients (7.7%), with the median minimum dosage reduced from 20 mg/day (range 15–45) to 15 mg/day (range 0–50) (p=0.006221). Moreover, immunosuppressive agents were cut down on types and dosage in 15 (57.7%) and 23 patients (88.5%), respectively, and were totally quitted in 5 cases (19.2%). Slight elevated liver and renal function parameters were detected in one and two patients, respectively. No other severe adverse events occurred. The serum autoantibodies were all negative during treatment with IFNα2a. Conclusions IFNα2a, in combination with corticosteroids and immunosuppressants, was effective and relatively safe in refractory BDU, with a potential steroid- and immunosuppressive agent-sparing effect. Disclosure of Interest None declared" @default.
• W2910394076 created "2019-01-25" @default.
• W2910394076 creator A5006295504 @default.
• W2910394076 creator A5008382096 @default.
• W2910394076 creator A5009256113 @default.
• W2910394076 creator A5054739067 @default.
• W2910394076 creator A5069473462 @default.
• W2910394076 creator A5075743683 @default.
• W2910394076 creator A5079767292 @default.
• W2910394076 date "2018-06-01" @default.
• W2910394076 modified "2023-09-27" @default.
• W2910394076 title "AB0710 Interferon Α2a for the treatment of refractory behÇet’s disease uveitis" @default.
• W2910394076 doi "https://doi.org/10.1136/annrheumdis-2018-eular.3453" @default.
• W2910394076 hasPublicationYear "2018" @default.
• W2910394076 type Work @default.
• W2910394076 sameAs 2910394076 @default.
• W2910394076 citedByCount "0" @default.
• W2910394076 crossrefType "proceedings-article" @default.
• W2910394076 hasAuthorship W2910394076A5006295504 @default.
• W2910394076 hasAuthorship W2910394076A5008382096 @default.
• W2910394076 hasAuthorship W2910394076A5009256113 @default.
• W2910394076 hasAuthorship W2910394076A5054739067 @default.
• W2910394076 hasAuthorship W2910394076A5069473462 @default.
• W2910394076 hasAuthorship W2910394076A5075743683 @default.
• W2910394076 hasAuthorship W2910394076A5079767292 @default.
• W2910394076 hasBestOaLocation W29103940761 @default.
• W2910394076 hasConcept C121332964 @default.
• W2910394076 hasConcept C126322002 @default.
• W2910394076 hasConcept C141071460 @default.
• W2910394076 hasConcept C142424586 @default.
• W2910394076 hasConcept C203014093 @default.
• W2910394076 hasConcept C2776194053 @default.
• W2910394076 hasConcept C2776804153 @default.
• W2910394076 hasConcept C2777138892 @default.
• W2910394076 hasConcept C2779134260 @default.
• W2910394076 hasConcept C2779384505 @default.
• W2910394076 hasConcept C2781428731 @default.
• W2910394076 hasConcept C71924100 @default.
• W2910394076 hasConcept C87355193 @default.
• W2910394076 hasConcept C90924648 @default.
• W2910394076 hasConceptScore W2910394076C121332964 @default.
• W2910394076 hasConceptScore W2910394076C126322002 @default.
• W2910394076 hasConceptScore W2910394076C141071460 @default.
• W2910394076 hasConceptScore W2910394076C142424586 @default.
• W2910394076 hasConceptScore W2910394076C203014093 @default.
• W2910394076 hasConceptScore W2910394076C2776194053 @default.
• W2910394076 hasConceptScore W2910394076C2776804153 @default.
• W2910394076 hasConceptScore W2910394076C2777138892 @default.
• W2910394076 hasConceptScore W2910394076C2779134260 @default.
• W2910394076 hasConceptScore W2910394076C2779384505 @default.
• W2910394076 hasConceptScore W2910394076C2781428731 @default.
• W2910394076 hasConceptScore W2910394076C71924100 @default.
• W2910394076 hasConceptScore W2910394076C87355193 @default.
• W2910394076 hasConceptScore W2910394076C90924648 @default.
• W2910394076 hasLocation W29103940761 @default.
• W2910394076 hasOpenAccess W2910394076 @default.
• W2910394076 hasPrimaryLocation W29103940761 @default.
• W2910394076 hasRelatedWork W1988413772 @default.
• W2910394076 hasRelatedWork W1999995422 @default.
• W2910394076 hasRelatedWork W2012131538 @default.
• W2910394076 hasRelatedWork W2024164398 @default.
• W2910394076 hasRelatedWork W2048444556 @default.
• W2910394076 hasRelatedWork W2054538887 @default.
• W2910394076 hasRelatedWork W2055800764 @default.
• W2910394076 hasRelatedWork W2076064330 @default.
• W2910394076 hasRelatedWork W2078470312 @default.
• W2910394076 hasRelatedWork W2102997845 @default.
• W2910394076 hasRelatedWork W2113682734 @default.
• W2910394076 hasRelatedWork W2319130845 @default.
• W2910394076 hasRelatedWork W2327990857 @default.
• W2910394076 hasRelatedWork W2330255297 @default.
• W2910394076 hasRelatedWork W2518834971 @default.
• W2910394076 hasRelatedWork W2560057131 @default.
• W2910394076 hasRelatedWork W2570329466 @default.
• W2910394076 hasRelatedWork W2746067027 @default.
• W2910394076 hasRelatedWork W2930413106 @default.
• W2910394076 hasRelatedWork W3100723688 @default.
• W2910394076 isParatext "false" @default.
• W2910394076 isRetracted "false" @default.
• W2910394076 magId "2910394076" @default.
• W2910394076 workType "article" @default.